Botulinum toxin type B for treatment of axillar hyperhidrosis

被引:65
|
作者
Dressler, D
Saberi, FA
Benecke, R
机构
[1] Univ Rostock, Dept Neurol, D-18147 Rostock, Germany
[2] Klinikum Nord, Botulinum Toxin Clin, Dept Neurol, Hamburg, Germany
关键词
botulinum toxin type B; therapy; axillar hyperhydrosis; conversion factor;
D O I
10.1007/s00415-002-0929-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recently, botulinum toxin type B (BT-B) became commercially available for treatment of cervical dystonia. It is the aim of this study to explore its use for treatment of bilateral axillar hyper-hydrosis (HH). For this we directly compared the antihyperhydrotic effect of BTB (NeuroBloc(R)/MyoBloc(TM)) with that of botulinum toxin type A (BT-A) (Botox(R)). 9 patients (HD group) received BT-A 100MU unilaterally and BT-B 4000MU contralaterally. 10 patients (LD group) received BT-A 100MU and BT-B 2000MU All patients were blinded as to which preparation was used in which side. All patients except one reported excellent HH improvement in both axillae. None of the patients had residual HH on clinical examination. The duration of HH improvement until first recurrence in the HD group was 16.0 +/- 4.3 weeks in the BT-A treated axillar and 16.4 +/- 4.5 weeks in the BT-B treated axillae (Wilcoxon rank-sum test, p = 0.336). In the LD group it was 16.4 +/- 5.3 weeks in the BT-B treated axillae and 17.1 +/- 5.7 weeks in the BT-A treated axillae (Wilcoxon rank-sum test, p = 0.059). There was also no difference in the duration of HH improvement between the axillae treated with BT-B 4000MU and BT-B 2000MU (Wilcoxon rank-sum test, p = 0.712). 5 out of 9 patients in the HD group (chi-square test, p = 0.025) and 7 out of 10 patients in the LD group (chi-square test, p = 0.008) reported more application discomfort in the BT-B treated axillae. In 6 out of 9 patients in the HD group (chi-square test, p = 0.014) and in 6 out of 10 patients in the LD group (chi-square test, p = 0.014) the onset of HH improvement appeared earlier in the BT-B treated axillae. One patient in the HD group reported dryness of the mouth and eyes and accomodation difficulties. BT-B is a safe and efficient treatment for axillar HH. Doses of BT-B 2000MU per axilla seem sufficient indicating a conversion factor between BT-A and BT-B in the order of 1:20. With a conversion factor for cervical dystonia in the order of 1:40 the autonomic nervous system seems to be relatively more sensitive to BT-B than to BT-A compared with the motor system.
引用
收藏
页码:1729 / 1732
页数:4
相关论文
共 50 条
  • [1] Botulinum toxin type B for treatment of axillar hyperhidrosis
    Dirk Dressler
    Fereshte Adib Saberi
    Reiner Benecke
    Journal of Neurology, 2002, 249 : 1729 - 1732
  • [2] Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis
    Dressler, D
    Benecke, R
    EUROPEAN NEUROLOGY, 2003, 49 (01) : 34 - 38
  • [3] HYPERHIDROSIS: QUALITY OF LIFE AND TREATMENT WITH BOTULINUM TOXIN TYPES A AND B
    Rystedt, Alma
    Swartling, Lovisa
    Swartling, Carl
    TOXICON, 2018, 156 : S100 - S100
  • [4] Effective treatment of frontal hyperhidrosis with botulinum toxin A
    Kinkelin, I
    Hund, M
    Naumann, M
    Hamm, H
    BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (04) : 824 - 827
  • [5] Botulinum Toxin Type B in the Treatment of Residual Limb Hyperhidrosis for Lower Limb Amputees A Pilot Study
    Kern, Uwe
    Kohl, Matthias
    Seifert, Ulrich
    Schlereth, Tanja
    AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2011, 90 (04) : 321 - 329
  • [6] Modified protocol for the application of botulinum toxin type A for hyperhidrosis of the nose
    Castro, Elisabeth
    Rocha-Pereira, Petronila
    Santos-Silva, Alice
    Coimbra, Susana
    Silva, Alice Santos
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2013, 52 (11) : 1400 - 1432
  • [7] How to save botulinum toxin A in the treatment of focal axillary hyperhidrosis
    Bechara, F. G.
    Sand, M.
    Hoffmann, K.
    DERMATOLOGY, 2006, 213 (04) : 356 - 356
  • [8] First application of botulinum toxin type B to treat ENT patients with secondary treatment failure of botulinum toxin type A
    Guntinas-Lichius, O
    HNO, 2004, 52 (01) : 53 - 56
  • [9] Efficacy and Safety of Botulinum Toxin B in Focal Hyperhidrosis: A Narrative Review
    Campanati, Anna
    Diotallevi, Federico
    Radi, Giulia
    Martina, Emanuela
    Marconi, Barbara
    Bobyr, Ivan
    Offidani, Annamaria
    TOXINS, 2023, 15 (02)
  • [10] Our Trick to Control the Depth of Injection of the Botulinum Toxin in the Treatment of Hyperhidrosis
    Blugerman, Guillermo
    Schavelzon, Diego
    Labaronnie, Honorio
    Markowsky, Andrea
    D'Angelo, Jorge
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2011, 127 (06) : 165E - 166E